CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-20 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −5,833 | $26.12 | $152K | 562,080 |
| 2026-01-20 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −5,083 | $26.11 | $133K | 25,812 |
| 2026-01-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,300 | $26.83 | $223K | 395,775 |
| 2026-01-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −200 | $27.40 | $5K | 395,575 |
| 2025-12-31 | Bredt David Chief Scientific Officer | Grant or award | −18,000 | 410,642 | ||
| 2025-12-31 | Bredt David Chief Scientific Officer | Sale | −6,567 | $30.05 | $197K | 404,075 |
| 2025-12-31 | Yeleswaram Krishnaswamy Chief Development Officer | Grant or award | +9,000 | 299,831 | ||
| 2025-12-31 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | −2,840 | $30.05 | $85K | 296,991 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,441 | $28.84 | $70K | 571,305 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,792 | $30.04 | $84K | 568,513 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −600 | $31.04 | $19K | 567,913 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,147 | $28.84 | $62K | 33,831 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,421 | $30.04 | $73K | 31,410 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −515 | $31.04 | $16K | 30,895 |
| 2025-12-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −7,704 | $29.95 | $231K | 393,438 |
| 2025-12-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −796 | $30.68 | $24K | 392,642 |
| 2025-11-26 | Gault Cheryl Chief Operating Officer | Option exercise 10b5-1 | +5,000 | $1.80 | $9K | 176,928 |
| 2025-11-26 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −5,000 | $30.10 | $150K | 171,928 |
| 2025-11-26 | Gault Cheryl Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 105,407 | ||
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,777 | $24.92 | $69K | 576,802 |
Page 5 of 10 · 186 trades